{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:24:33Z","timestamp":1789428273373,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was supported by ALF funding from Region \u00d6rebro County","award":["grant number OLL-1021286"],"award-info":[{"award-number":["grant number OLL-1021286"]}]},{"DOI":"10.13039\/501100003509","name":"\u00d6rebro University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003509","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pseudoprogression is an atypical response pattern observed during treatment with immune checkpoint inhibitors (CPIs) that can complicate clinical decision-making. It is characterized by initial radiologic progression followed by subsequent tumor regression or stabilization, with confirmation requiring repeat imaging. We aimed to characterize the clinical and imaging features of confirmed pseudoprogression in solid tumors treated with CPIs using pooled study data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched MEDLINE, Embase,\u00a0and Web of Science through December 2025. Prospective and retrospective cohort studies and randomized trials reporting confirmed pseudoprogression during CPI therapy were eligible. Two independent reviewers performed study selection and data extraction using predefined criteria. Study quality was assessed using the Joanna Briggs Institute checklist. Pooled analyses were conducted with RevMan and Stata. Outcomes included time to initial radiologic progression, magnitude of tumor burden increase, occurrence of new lesions, changes in nontarget lesions, and subsequent objective response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen retrospective studies\u00a0were included; most applied iRECIST criteria. The pooled median time to initial progression was 2.52\u00a0months (95% CI, 1.54\u20133.51). Mean tumor burden increase was 33.0% (95% CI, 22.7\u201343.3), and new lesions occurred in 35.3% of cases. Tumor burden increases\u2009&gt;\u2009100% were rare (3.9%). Despite initial progression, 41.8% subsequently achieved partial response and 6.4% complete response without therapy change. Median time to best response was 2.79\u00a0months (95% CI, 0.62\u20137.20).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pseudoprogression typically occurs early during CPI therapy and is associated with modest tumor growth. Marked tumor increases are uncommon and may help distinguish true progression. Careful clinical and radiologic assessment remains essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-026-04433-9","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:55:09Z","timestamp":1780923309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing the clinical assessment of pseudoprogression in patients with solid tumors treated with checkpoint inhibitors: a systematic literature review and meta-analysis of associated features"],"prefix":"10.1007","volume":"75","author":[{"given":"Georgios","family":"Fountoukidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Tina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"G\u00f6thlin-Eremo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Ullenhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Valachis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"3","key":"4433_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/annonc\/mdz003","volume":"30","author":"E Borcoman","year":"2019","unstructured":"Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R et al (2019) Novel patterns of response under immunotherapy. Ann Oncol 30(3):385\u2013396","journal-title":"Ann Oncol"},{"key":"4433_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00114","volume":"3","author":"E Pons-Tostivint","year":"2019","unstructured":"Pons-Tostivint E, Latouche A, Vaflard P, Ricci F, Loirat D, Hescot S et al (2019) Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials. JCO Precis Oncol 3:1\u201310","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"4433_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40644-023-00580-9","volume":"23","author":"S M\u00f6nch","year":"2023","unstructured":"M\u00f6nch S, Heimer MM, Winkelmann M, Guertler A, Schlaak M, Tufman A et al (2023) Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors. Cancer Imaging 23(1):58","journal-title":"Cancer Imaging"},{"issue":"1","key":"4433_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21037\/jtd.2018.12.47","volume":"11","author":"CE Onesti","year":"2019","unstructured":"Onesti CE, Fr\u00e8res P, Jerusalem G (2019) Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients\u2019 treatment. J Thorac Dis 11(1):35\u201338","journal-title":"J Thorac Dis"},{"issue":"1","key":"4433_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1148\/radiol.2020200443","volume":"297","author":"HJ Park","year":"2020","unstructured":"Park HJ, Kim KW, Pyo J, Suh CH, Yoon S, Hatabu H et al (2020) Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: A systematic review and meta-analysis. Radiology 297(1):87\u201396","journal-title":"Radiology"},{"issue":"1","key":"4433_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40644-019-0281-x","volume":"20","author":"T Persigehl","year":"2020","unstructured":"Persigehl T, Lennartz S, Schwartz LH (2020) iRECIST: how to do it. Cancer Imaging 20(1):2","journal-title":"Cancer Imaging"},{"issue":"1","key":"4433_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4103\/jcrt.jcrt_1898_22","volume":"20","author":"IK Yirgin","year":"2024","unstructured":"Yirgin IK, Dogan I, Engin G, Vatansever S, Erturk SM (2024) Immune checkpoint inhibitors: assessment of the performance and the agreement of iRECIST, irRC, and irRECIST. J Cancer Res Ther 20(1):156\u2013162","journal-title":"J Cancer Res Ther"},{"issue":"10","key":"4433_CR8","doi-asserted-by":"publisher","first-page":"7625","DOI":"10.21037\/jtd-2025-1381","volume":"17","author":"A Huang","year":"2025","unstructured":"Huang A, Xie M, Wu C, Gao J, Ma X, Deng H et al (2025) Continuing immune checkpoint inhibitors after pseudoprogression improves survival in lung cancer patients: a systematic review and meta-analysis. J Thorac Dis 17(10):7625\u20137637","journal-title":"J Thorac Dis"},{"issue":"10","key":"4433_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.clon.2024.06.002","volume":"36","author":"S Morrissey","year":"2024","unstructured":"Morrissey S, Vasconcelos AG, Wang CL, Wang S, Cunha GM (2024) Pooled rate of pseudoprogression, patterns of response, and tumor burden analysis in patients undergoing immunotherapy oncologic trials for different malignancies. Clin Oncol (R Coll Radiol) 36(10):624\u2013631","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"4433_CR10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"4","key":"4433_CR11","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00330-020-07249-y","volume":"31","author":"FS Ahmed","year":"2021","unstructured":"Ahmed FS, Dercle L, Goldmacher GV, Yang H, Connors D, Tang Y et al (2021) Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. Eur Radiol 31(4):1853\u201362","journal-title":"Eur Radiol"},{"issue":"16","key":"4433_CR12","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1158\/1078-0432.CCR-20-0020","volume":"26","author":"L Basler","year":"2020","unstructured":"Basler L, Gabry\u015b HS, Hogan SA, Pavic M, Bogowicz M, Vuong D et al (2020) Radiomics, tumor volume, and blood biomarkers for early prediction of pseudoprogression in patients with metastatic melanoma treated with immune checkpoint inhibition. Clin Cancer Res 26(16):4414\u20134425","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4433_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","volume":"19","author":"JA Beaver","year":"2018","unstructured":"Beaver JA, Hazarika M, Mulkey F, Mushti S, Chen H, He K et al (2018) Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol 19(2):229\u2013239","journal-title":"Lancet Oncol"},{"issue":"1","key":"4433_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00262-020-02647-z","volume":"70","author":"A Bernard-Tessier","year":"2021","unstructured":"Bernard-Tessier A, Baldini C, Castanon E, Martin P, Champiat S, Hollebecque A et al (2021) Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunol Immunother 70(1):221\u2013232","journal-title":"Cancer Immunol Immunother"},{"key":"4433_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2020.11.009","volume":"144","author":"R Colle","year":"2021","unstructured":"Colle R, Radzik A, Cohen R, Pellat A, Lopez-Tabada D, Cachanado M et al (2021) Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer. Eur J Cancer 144:9\u201316","journal-title":"Eur J Cancer"},{"issue":"3","key":"4433_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jtho.2018.10.167","volume":"14","author":"D Fujimoto","year":"2019","unstructured":"Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH et al (2019) Pseudoprogression in previously treated patients with Non-Small Cell Lung Cancer who received Nivolumab monotherapy. J Thorac Oncol 14(3):468\u2013474","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4433_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.clgc.2023.03.003","volume":"21","author":"L Haaker","year":"2023","unstructured":"Haaker L, Baldewijns M, De Wever L, Albersen M, Debruyne PR, Wynendaele W et al (2023) Pseudoprogression and mixed responses in Metastatic Renal Cell Carcinoma patients treated with Nivolumab: a retrospective analysis. Clin Genitourin Cancer 21(4):442\u2013451","journal-title":"Clin Genitourin Cancer"},{"issue":"13","key":"4433_CR18","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O et al (2016) Evaluation of immune-related response criteria and RECIST v11 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 34(13):1510\u20137","journal-title":"J Clin Oncol."},{"issue":"1","key":"4433_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cncr.32522","volume":"126","author":"IP da Silva","year":"2020","unstructured":"da Silva IP, Lo S, Quek C, Gonzalez M, Carlino MS, Long GV et al (2020) Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. Cancer 126(1):86\u201397","journal-title":"Cancer"},{"key":"4433_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","volume":"88","author":"M Tazdait","year":"2018","unstructured":"Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S et al (2018) Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 88:38\u201347","journal-title":"Eur J Cancer"},{"issue":"1","key":"4433_CR21","doi-asserted-by":"publisher","first-page":"1776058","DOI":"10.1080\/2162402X.2020.1776058","volume":"9","author":"SE Won","year":"2020","unstructured":"Won SE, Park HJ, Byun S, Pyo J, Kim JH, Choi CM et al (2020) Impact of pseudoprogression and treatment beyond progression on outcome in patients with Non-Small Cell Lung Cancer treated with immune checkpoint inhibitors. Oncoimmunology 9(1):1776058","journal-title":"Oncoimmunology"},{"issue":"5","key":"4433_CR22","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V et al (2017) Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol 28(5):1130\u20131136","journal-title":"Ann Oncol"},{"issue":"8","key":"4433_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/CJI.0000000000000569","volume":"48","author":"AK Steimle","year":"2025","unstructured":"Steimle AK, Cho SY, Menon N, Jeraj R, Birbrair A, Albertini MR et al (2025) ctDNA dynamics identifies pseudoprogression in a metastatic melanoma patient treated with nivolumab\/relatlimab. J Immunother 48(8):325\u2013328","journal-title":"J Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04433-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04433-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04433-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:29:17Z","timestamp":1781357357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04433-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4433"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04433-9","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conflict of interest GU reports potential conflicts of interest in recent three years: Educational events and\/or meetings arranged by MSD, BMS, Novartis, Astellas, Astrazeneca, Sanofi, Regeneron and Pierre Fabre. AV reports institutional consultancy fees (for educational purposes) from AstraZeneca, Daiichi Sankyo, Gilead, MSD, Lilly, Novartis and Pfizer. He reports institutional unrestricted grant from Roche and MSD unrelated to current study. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"170"}}